New cocktail of cancer drugs shows promise for tough brain tumors
NCT ID NCT07191431
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs—orelabrutinib, selinexor, and a chemotherapy drug—in 25 people with relapsed or refractory central nervous system lymphoma, a type of brain cancer. The goal is to see if this mix can shrink tumors better than current treatments. Participants will receive the drugs in cycles over 18 weeks, with possible maintenance therapy. This is an early-stage trial, so the main focus is safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Orelabrutinib, selinexor, and methotrexate (or alternatives thiotepa or temozolomide)
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat brain lymphoma, potentially improving response rates.
What could go wrong
This is a very small early trial with only 25 participants, so results may not apply broadly. The drug combo has significant side effects, and long-term benefits are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA CNS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••